GI Dynamics, a company engaged in non-surgical, endoscopic treatments for type 2 diabetes and obesity, has appointed Wade Fox as vice president of marketing and named Karl Blohm to the newly created role of vice president, international.
The appointments are in preparation to launch EndoBarrier Gastrointestinal Liner, a non-surgical therapeutic for the treatment of type 2 diabetes and obesity, in Europe this fall.
Fox joins GI Dynamics from Covidien where he served as global director of strategic marketing, biologics and tissue repair. He trained the sales force in product repositioning and implemented a global go-to-market strategy.
Prior to his role at Covidien, Fox held various marketing positions with Tissuescience, Diomed, Abiomed, Smith and Nephew, Endoscopy Division and Baxter.
Blohm is a strategic commercial executive and general manager with more than 20 years of medical device industry experience, combining capital equipment and medical devices in large company and small company environments.
Prior to joining GI Dynamics, Blohm served as partner and general manager of AB Medica, a national medical technology distribution company he established in France.
Before joining AB Medica, Blohm played a key role in leading the successful launches of innovative medical devices and technologies in his previous positions at EndoGastric Solutions, Accuray Europe and Siemens.
GI Dynamics CEO Stuart Randle said that the firm is confident that Wade’s expertise in marketing medical devices, and Karl’s experience in successfully launching technologies in Europe, will add substantial value to its team and further strengthen the commercialisation efforts in support of the EndoBarrier launch.